Non-Hodgkin Lymphoma
Conference Coverage
Molecule increases TRAIL expression to fight NHL
Convention Center, site of the AACR Annual Meeting 2015 PHILADELPHIA—When current treatment approaches failed to save a young patient with non-...
Conference Coverage
‘Watch and wait’ may be inadvisable for CLL
PHILADELPHIA—Withholding treatment from chronic lymphocytic leukemia (CLL) patients because they are of advanced age and have comorbidities may...
News
miR expression may predict long-term prognosis in DLBCL
Photo courtesy of NIH MicroRNA (miR) expression may help us predict long-term prognosis in diffuse large B-cell lymphoma (DLBCL), according to a...
News
Epigenomic findings may help predict relapse in DLBCL
Photo by Rhoda Baer Epigenomic heterogeneity at diagnosis may predict relapse in diffuse large B-cell lymphoma (DLBCL), according to research...
News
New mAb can overcome resistance to other mAbs
Photo courtesy of the University of Southampton A newly developed monoclonal antibody (mAb) can reverse resistance to other mAbs in chronic...
News
Technique helps determine DLBCL subtypes
Photo by Darren Baker A new technique can quickly and easily differentiate the two major subtypes of diffuse large B-cell lymphoma (DLBCL),...
News
Combo improves PFS in untreated CLL
Results of a phase 3 study suggest that adding ofatumumab to chlorambucil can improve progression-free survival (PFS) in treatment-naïve patients...
News
Inhibitor controls WM long-term
Photo by Sam Odgen Updated results of a phase 2 trial suggest the Bruton’s tyrosine kinase inhibitor ibrutinib can control Waldenstrom’s...
News
Inhibitor gets orphan designation for DLBCL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CUDC-907 for the treatment of diffuse large B-cell lymphoma (...
News
Test predicts DLBCL relapse better than CT, team says
Photo by Larry Young Surveillance of circulating tumor DNA (ctDNA) can help predict relapse in most patients with diffuse large B-cell lymphoma...
News
FDA grants drug orphan designation for DLBCL
The US Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal toll-like receptors (...